These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20550118)

  • 1. Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
    Hu Q; Yin L; Jagusch C; Hille UE; Hartmann RW
    J Med Chem; 2010 Jul; 53(13):5049-53. PubMed ID: 20550118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
    Hu Q; Jagusch C; Hille UE; Haupenthal J; Hartmann RW
    J Med Chem; 2010 Aug; 53(15):5749-58. PubMed ID: 20684610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
    Hu Q; Negri M; Jahn-Hoffmann K; Zhuang Y; Olgen S; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
    Bioorg Med Chem; 2008 Aug; 16(16):7715-27. PubMed ID: 18674917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.
    Hille UE; Hu Q; Vock C; Negri M; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
    Eur J Med Chem; 2009 Jul; 44(7):2765-75. PubMed ID: 19211174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
    Pinto-Bazurco Mendieta MA; Negri M; Jagusch C; Müller-Vieira U; Lauterbach T; Hartmann RW
    J Med Chem; 2008 Aug; 51(16):5009-18. PubMed ID: 18672868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.
    Wang M; Fang Y; Gu S; Chen F; Zhu Z; Sun X; Zhu J
    Eur J Med Chem; 2017 May; 132():157-172. PubMed ID: 28350999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
    Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP17 inhibitors for prostate cancer treatment--an update.
    Moreira VM; Salvador JA; Vasaitis TS; Njar VC
    Curr Med Chem; 2008; 15(9):868-99. PubMed ID: 18473796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modelling.
    Pinto-Bazurco Mendieta MA; Negri M; Hu Q; Hille UE; Jagusch C; Jahn-Hoffmann K; Müller-Vieira U; Schmidt D; Lauterbach T; Hartmann RW
    Arch Pharm (Weinheim); 2008 Oct; 341(10):597-609. PubMed ID: 18720339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of fluorine substitution in biphenyl methylene imidazole-type CYP17 inhibitors for the treatment of prostate carcinoma.
    Hu Q; Negri M; Olgen S; Hartmann RW
    ChemMedChem; 2010 Jun; 5(6):899-910. PubMed ID: 20437447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New benzothieno[2,3-
    Khalil NA; Ahmed EM; Zaher AF; Sobh EA; El-Sebaey SA; El-Zoghbi MS
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1839-1859. PubMed ID: 34338119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.
    Haidar S; Hartmann RW
    Pharmazie; 2017 Sep; 72(9):529-536. PubMed ID: 29441980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imidazole substituted biphenyls: a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer.
    Wachall BG; Hector M; Zhuang Y; Hartmann RW
    Bioorg Med Chem; 1999 Sep; 7(9):1913-24. PubMed ID: 10530940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
    Hou Q; He C; Lao K; Luo G; You Q; Xiang H
    Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.
    Pinto-Bazurco Mendieta MA; Hu Q; Engel M; Hartmann RW
    J Med Chem; 2013 Aug; 56(15):6101-7. PubMed ID: 23859149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition.
    Krug SJ; Hu Q; Hartmann RW
    J Steroid Biochem Mol Biol; 2013 Mar; 134():75-9. PubMed ID: 23142656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP17 inhibitors for prostate cancer therapy.
    Vasaitis TS; Bruno RD; Njar VC
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):23-31. PubMed ID: 21092758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
    J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
    Leroux F
    Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.